← Leaderboards
Lori Ferrins
Northeastern University
$4,619,768
Attributed
$7,330,394
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2020–25$2.5M$1.9M$1.3M$625K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,330,394 · 6
By mechanism
R01$6,334,267 · 4
R33$806,492 · 1
R21$189,635 · 1
Top collaborators
- Kelly Chibale5 shared
- Timothy M Willson5 shared
- Kojo Mensa-Wilmot4 shared
- Julia R Koehler1 shared
- Mary J Ondrechen1 shared
Most similar at Northeastern University
Same institution · by research overlap
- Mary J Ondrechen$94,818
Others in their field
Other Emerging Leaders on “Drug Discovery”
- Leonard Freedman · Leidos Biomedical Research, Inc.$255,277,443
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- John Damon Chodera · Sloan-Kettering Inst Can Research$64,994,606
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Gary Kobinger · University Of Texas Med Br Galveston$41,631,815
Research focus
Drug DiscoveryPharmaceutical ChemistryDrug KineticsSeriesToxic EffectLeadParasitesNovel TherapeuticsPhenotypeStructureCellsMouse ModelInhibitorProteomicsPharmaceutical PreparationsFundingIn VivoInfectionIn Vivo ModelDrug MetabolismPropertyWorld Health OrganizationCollaborationsGenetic
Grant awards (17)
Optimization and Modes of Action of NEU-4438, a New Anti-trypanosome Lead Drug$666,604
R01 · FY2025 · AI
Repurposing human kinase inhibitor chemotypes for Neglected Tropical Diseases$400,861
R01 · FY2025 · AI · contact PI
Novel Structure-Based Therapeutic Discovery for Balamuthia mandrillaris$189,635
R21 · FY2025 · AI · contact PI
Optimization and Modes of Action of NEU-4438, a New Anti-trypanosome Lead Drug$673,815
R01 · FY2024 · AI
Repurposing human kinase inhibitor chemotypes for Neglected Tropical Diseases$400,438
R01 · FY2024 · AI · contact PI
Repurposing kinase inhibitor chemotypes as antimalarials$279,425
R01 · FY2024 · AI
Optimization and Modes of Action of NEU-4438, a New Anti-trypanosome Lead Drug$675,005
R01 · FY2023 · AI
Inhibiting sequential biosynthetic steps of a fungal-specific organelle$445,444
R01 · FY2023 · AI
Repurposing human kinase inhibitor chemotypes for Neglected Tropical Diseases$413,962
R01 · FY2023 · AI · contact PI
Lead optimization of hits identified from virtual and experimental screens of multiple industrial libraries DNDi$403,246
R33 · FY2023 · AI · contact PI
Repurposing kinase inhibitor chemotypes as antimalarials$290,699
R01 · FY2023 · AI
Optimization and Modes of Action of NEU-4438, a New Anti-trypanosome Lead Drug$681,374
R01 · FY2022 · AI
Repurposing human kinase inhibitor chemotypes for Neglected Tropical Diseases$409,733
R01 · FY2022 · AI · contact PI
Lead optimization of hits identified from virtual and experimental screens of multiple industrial libraries DNDi$403,246
R33 · FY2022 · AI · contact PI
Repurposing kinase inhibitor chemotypes as antimalarials$304,092
R01 · FY2022 · AI
Repurposing kinase inhibitor chemotypes as antimalarials$342,815
R01 · FY2021 · AI
Repurposing kinase inhibitor chemotypes as antimalarials$350,000
R01 · FY2020 · AI